ClinicalTrials.gg
Not yet recruitingNCT07345637FXS887-I101Updated Jan 16, 2026

Phase I Study of FXS887 in the Treatment of Solid Tumors

A Phase 1 interventional study of FXS887 in Solid Tumor Refractory to Conventional Treatment, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.

Read the detailed description

There will be two parts for this study:

Phase 1a is a dose-escalation, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. Approximately 14 subjects are expected to be enrolled.

Dose escalation will adopt a combination of "accelerated titration" and "3+3" design. The initial 2 dose cohorts will use the accelerated titration, while the 3+3 design will be implemented starting in other dose cohorts. If a Dose Limiting Toxicity (DLT) event or a study treatment-related adverse event of grade ≥2 occurs during the DLT observation period, the current dose cohort will switch to the 3+3 design. Eligible subjects will receive oral FXS887 once daily. The DLT observation period is within 28 days after the first dose (Cycle 1), followed by multiple-dose studies in Cycle 2 and subsequent cycles. Treatment will continue until the subject experiences disease progression, death, unacceptable toxicity, withdrawal of informed consent, or other reasons requiring discontinuation of study treatment (whichever occurs first).

Phase 1b is an open-label, dose-expansion study that plans to enroll eligible patients with advanced solid tumors. The sample size will be determined based on the results of the Phase 1a, to further evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of FXS887 at the recommended expansion dose(s).

02

Conditions studied

  • Solid Tumor Refractory to Conventional Treatment
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years, male or female;
  2. Participants must fully understand the requirements of the study and voluntarily sign the written ;
  3. Participants with histologically/ confirmed advanced solid tumors who have received ≥ 1 prior to enrollment in the study and experienced failure of standard therapy (disease progression or intolerance);
  4. Per (RECIST) v1.1, participants must have at least one measurable target lesion;
  5. (ECOG) performance status of 0 to 1;
  6. Estimated of ≥ 12 weeks;
  7. Participants must have adequate organ and bone marrow function.
  8. For female participants of childbearing age, the serum pregnancy test within 7 days prior to the first dose of the study drug must be negative; eligible participants of (both males and females) must agree to use reliable methods (hormonal, barrier, abstinence, etc.) with their partners during the study period and for at least 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Within the of prior anti-tumor medication treatment (4 weeks or 5 half-lives after the last dose, whichever is longer) prior to the first dose of FXS887;
  2. Have participated in another clinical study within 4 weeks prior to the first dose of FXS887;
  3. Have a history of to any known components of FXS887 or its analogues;
  4. Have intolerance to ATR inhibitors or have received ATR inhibitors within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of FXS887;
  5. Need to take strong inhibitors and/or inducers, as well as P-gp (P-glycoprotein) inhibitors and/or inducers within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of FXS887 and during the study period;
  6. Need to take drugs known to prolong the during the study period;
  7. Have had other malignant tumors within 2 years prior to the first dose of FXS887, except for local tumors that have been cured and judged by the investigator to have a low risk of recurrence;
  8. Have received radiation therapy within 14 days prior to the first dose of FXS887;
  9. Have not recovered from adverse events caused by prior anti-cancer treatment (recovered to Grade 1 or baseline), except for alopecia, pigmentation of any grade, Grade ≤2 peripheral sensory neuropathy, and items explicitly specified in the inclusion criteria;
  10. Have nausea and vomiting, chronic gastrointestinal diseases including but not limited to active diverticulitis and symptomatic peptic ulcers, inability to swallow oral medications, or a history of extensive small bowel resection or other conditions that significantly impair gastrointestinal absorption as judged by the investigator;
  11. Have undergone major surgery within 2 weeks prior to the first dose or have not recovered from surgical complications;
  12. Have primary central nervous system (CNS) tumors, meningeal , spinal cord compression, or brainstem metastasis; participants with known untreated or symptomatic or unstable disease are excluded; participants who have completed treatment for brain metastases (radiation therapy or surgery) with stable metastases and no relevant symptoms (without medication control) within 4 weeks prior to the first dose may be enrolled;
  13. Have severe cardiovascular diseases;
  14. Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage and medical intervention;
  15. Have active infections requiring treatment (e.g., participants are receiving anti-infective treatment) within 14 days prior to the first dose of FXS887, including virus (HCV), (HIV), uncontrolled active virus (HBV) infection, syphilis infection, known active tuberculosis, etc.
  16. Known infection with hepatitis B virus (HBV) or hepatitis C virus (HCV):

    • participants with controlled HBV infection (serum HBV-DNA \< 500 IU/mL or \< 2,000 copies/mL) are allowed to enroll in this study.
    • participants who are HCV antibody-positive with controlled infection [polymerase chain reaction (PCR) for serum HCV-RNA below the lower limit of detection] are allowed to enroll in this study.
  17. History of human immunodeficiency virus (HIV) infection;
  18. History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring therapy, or clinically active ILD;
  19. Known substance abuse or psychiatric disorder that may interfere with compliance with study requirements;
  20. Participants are pregnant, breastfeeding, or planning to become pregnant during the study period;
  21. Investigator considers the participant has other factors that may affect study results or interfere with participation in the entire study, including past or existing medical conditions, treatment or laboratory abnormalities, or unwillingness to comply with study procedures, restrictions, and requirements-any condition deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    FXS887

    This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. It mainly consists of two parts: the Phase Ia dose-escalation study and the Phase Ib dose-expansion study. Participants will receive FXS887 orally once-daily at determined dose levels on a 28-day cycle.

    Drug: FXS887

Interventions

  • DrugFXS887

    FXS887 is an innovative ATR inhibitor targeting ATR kinase.

06

What researchers measure

Primary outcomes

  1. Number of participants with DLTs

    DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined DLT criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (28 days) of treatment.

    Time frame: Up to Day 28

  2. Maximum tolerated dose (MTD) or Maximum administered dose(MAD)

    The MTD is defined as the highest dose level at which the proportion of subjects who experience Dose-Limiting Toxicity (DLT) is less than 1/3 during the DLT observation period. If the MTD is not established after the completion of the dose-escalation, the highest safe dose level will be defined as the MAD.

    Time frame: Up to 12 Months

  3. Incidence of Treatment-Emergent Adverse Events (TEAEs)[Safety and Tolerability]

    Number and frequency of subjects with adverse events, including changes in vital signs, electrocardiograms (ECGs), physical examinations, and laboratory parameters, graded according to NCI CTCAE v5.0.

    Time frame: From first dose of study drug until 30 days after the last dose.

  4. Phase 1a: recommended phase 2 dose (RP2D)

    The RP2D (Recommended Phase 2 Dose) determined based on comprehensive consideration of safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics), and efficacy data.

    Time frame: Up to 12 Months

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of FXS887

    Maximum observed plasma concentration of FXS887 following single and multiple doses.

    Time frame: From the day of first dose to 30 days after last dose of FXS887

  2. Area under the plasma concentration-time curve (AUC)of FXS887

    The area under the plasma concentration-time curve of FXS887 following single and multiple doses.

    Time frame: From the day of first dose to 30 days after last dose of FXS887

  3. Time to reach maximum plasma concentration (Tmax) of FXS887

    Time to reach maximum plasma concentration of FXS887 following single and multiple doses.

    Time frame: From the day of first dose to 30 days after last dose of FXS887

  4. Elimination Half-Life (t1/2) of FXS887

    Apparent terminal elimination half-life of FXS887 in plasma.

    Time frame: From the day of first dose to 30 days after last dose of FXS887

  5. Objective response rate, ORR

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.

  6. Progression Free Survival

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Apr 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 16, 2026
StartEst.
Jan 5, 2026
Primary completionEst.
Apr 28, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345637
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 5, 2026 (estimated)
Primary completion
Apr 28, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Xiaohua Wu
Contact
wu.xh@fudan.edu.cn
+86 21 6417 5590 ext. 81000
Jian Zhang
Contact
syner2000@163.com
86 21 6417 5590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion